Ampio Pharmaceuticals, Inc. (OTCPK: AMPE)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Ampio Pharmaceuticals, Inc. (OTCPK: AMPE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $207.88K and employs 6 people.
trading between 0.00 and 0.64.
Tweenvest scores Ampio Pharmaceuticals, Inc. across four factors: quality 26/100. Its strongest factor is quality.
AMPE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $207.88K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -10.66
- Dividend yield
- —
- Beta (5Y)
- 17.90
- 52-week high
- $0.64
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.14M
- Employees
- 6
- Next earnings
- —
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.
- ISIN
- US03209T3077
- Listed since
- Mar 31, 2010
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.